Comparing Invivo Therapeutics (NVIV) and Becton Dickinson and (BDX)

Invivo Therapeutics (NASDAQ: NVIV) and Becton Dickinson and (NYSE:BDX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Valuation & Earnings

Get Invivo Therapeutics alerts:

This table compares Invivo Therapeutics and Becton Dickinson and’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivo Therapeutics	N/A	N/A	-$26.74 million	($18.50)	-0.11
Becton Dickinson and	$12.09 billion	5.42	$1.10 billion	$9.48	25.86

Becton Dickinson and has higher revenue and earnings than Invivo Therapeutics. Invivo Therapeutics is trading at a lower price-to-earnings ratio than Becton Dickinson and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Invivo Therapeutics and Becton Dickinson and, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivo Therapeutics	0	1	0	0	2.00
Becton Dickinson and	0	4	11	0	2.73

Becton Dickinson and has a consensus target price of $239.67, indicating a potential downside of 2.23%. Given Becton Dickinson and’s stronger consensus rating and higher probable upside, analysts clearly believe Becton Dickinson and is more favorable than Invivo Therapeutics.

Institutional & Insider Ownership

84.1% of Becton Dickinson and shares are owned by institutional investors. 2.8% of Invivo Therapeutics shares are owned by insiders. Comparatively, 1.0% of Becton Dickinson and shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Invivo Therapeutics and Becton Dickinson and’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invivo Therapeutics	N/A	-194.69%	-144.68%
Becton Dickinson and	-0.46%	14.27%	5.24%

Volatility and Risk

Invivo Therapeutics has a beta of 2.67, suggesting that its stock price is 167% more volatile than the S&P 500. Comparatively, Becton Dickinson and has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

Dividends

Becton Dickinson and pays an annual dividend of $3.00 per share and has a dividend yield of 1.2%. Invivo Therapeutics does not pay a dividend. Becton Dickinson and pays out 31.6% of its earnings in the form of a dividend. Becton Dickinson and has raised its dividend for 46 consecutive years.

Summary

Becton Dickinson and beats Invivo Therapeutics on 11 of the 15 factors compared between the two stocks.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.